北京大学医学部精准神经外科与脑肿瘤研究中心于2019年正式获批成立，中心挂靠北京大学第三医院，由詹启敏院士任第一届学术委员会主任，张亚卓教授任名誉主任，杨军教授任中心主任。

研究领域及方向：

1、脑肿瘤精准诊疗方向：脑肿瘤的诊疗进入精准医疗时代——在生物样本库、基因检测平台及大数据平台的共同发展下，精准医学将带来全新的融合发展和变革，基于组学的精准治疗以及基于人工智能的手术决策和计划系统的基础与临床应用研究。

2、脑肿瘤脑成像新技术、新方法与智能影像方向：多模态虚拟现实成像及应用，DTI神经纤维束成像及应用，脑细胞外间隙成像及应用；手术导航与机器人系统。

3、扩展性脑病治疗前沿技术与临床应用研究：经细胞外间隙途径的脑肿瘤、其他脑病药物治疗基础研究，开展干细胞辅助脑肿瘤治疗的临床及基础研究，肿瘤切除后神经再生研究、神经损伤修复研究等；脑肿瘤相关性癫痫、脑积水的机制研究。

北京大学医学部精准神经外科与脑肿瘤研究中心以北医三院为核心，充分利用北京大学学科全面的综合优势，联合信息技术学院、工学院、基础医学院、药学院以及各附属医院，围绕临床脑病，尤其脑肿瘤的诊疗，形成跨学科交叉的研究团队。以临床脑病智能化诊疗为导向，在国内率先组织多个相关学科一起，为脑肿瘤患者提供、全面、智能、精准治疗的中心，以“振兴北大脑科学，打造顶级神经外科中心”为目标。

目前中心拥有院士4名，杰青1人，高级职称25人，团队成员涵盖神经外科、神经内科、基础医学、医学影像学、计算机信息技术学、分子影像学等领域，初步形成了以神经外科精准医疗、智能医疗为主体的学科交叉团队。挂靠单位北京大学第三医院，拥有磁共振设备8台，CT设备若干，可开展目前所有常规头部磁共振及CT检查；拥有自主研发世界首套磁示踪法细胞外间隙成像设备；拥有开展常规手术的高端显微镜、导航、电生理检测等，提供标本获取及病源保障。

近年来的重要科研成果及贡献

    1、首创磁示踪细胞外间隙成像分析法，成功解决了深部组织ECS信号采集的难题，并实现全脑尺度ECS的结构与其内分子运动等关键信息的同步处理分析及成像显示，提出基于该方法的脑细胞外间隙给药途径。

    2、研究胶质瘤中PLVAP的基因本体分析证明了该蛋白在胶质瘤相关免疫生物学过程中以及在炎症反应中的主要作用。发现大多数免疫细胞的浸润程度与PLVAP表达呈正相关，证明PLVAP与胶质瘤中免疫抑制免疫细胞浸润程度、不良生存率和不良病理类型显著相关，因此将PLVAP确定为基于胶质瘤的精确诊断和治疗策略的可行标志物和有前途的靶点。

    3、系统地探讨了成人胶质瘤的生物学特征和临床意义。发现S100A10特异且灵敏地指示间充质样分子亚型；胶质细胞过滤免疫细胞的水平与S100A10的表达呈正相关，使其成为胶质瘤诊断、治疗和预后评估中的一个有前途的生物标志物和潜在靶点。

机构负责人：杨军

联系人：于涛

邮箱：13901291211@163.com（杨军教授）

地址：北京市海淀区花园北路49号

Center for Precision Neurosurgery and Oncology of Peking University Health Science Center

Center for Precision Neurosurgery and Oncology of Peking University Health Science Center was established on June 6, 2019. The center is affiliated to the Peking University Third Hospital. Academician Qimin Zhan is the director of the first academic committee, Professor Yazhuo Zhang is the honorary director, and Professor Jun Yang is the director of the center.

Its specific research directions and fields include:

1. Accurate diagnosis and treatment of brain tumors: the diagnosis and treatment of brain tumors has entered the era of precision medicine. With the development and establishment of biological sample database, gene detection platform and big data platform, precision medicine will bring new development and change. We are committed to the basic and clinical application research of precision treatment and artificial intelligence based by surgery decision-making and planning system.

2. New technologies, methods and intelligent imaging of brain tumor: including multimodal virtual reality imaging and application, DTI nerve fiber imaging and application, brain extracellular space imaging and application, surgical navigation and robot system.

3. Research on advanced technology and clinical application of extended encephalopathy treatment: including basic research on drug treatment of brain tumor and other encephalopathy via extracellular space; clinical and basic research on stem cell-assisted brain tumor treatment; research on nerve regeneration after tumor resection; research on nerve injury and repair; research on the mechanism of brain tumor related epilepsy and hydrocephalus.

Center for Precision Neurosurgery and Oncology of Peking University Health Science Center based on the third Peking University Medical College, makes full use of the advantages of Peking University as a comprehensive university. Through the combination of School of information technology of Peking University, School of technology of Peking University, School of basic medicine of Peking University, School of pharmacy of Peking University and affiliated hospitals of Peking University, it focuses on the diagnosis and treatment of clinical encephalopathy, especially brain tumor to form an interdisciplinary research team system. Guided by the intelligent diagnosis and treatment of clinical encephalopathy, it takes the lead in combining multiple related disciplines in China to provide comprehensive and intelligent precision treatment center for brain tumor patients, with the goal of "revitalizing brain science of Peking University and building top neurosurgery center".

At present, the center has 4 academicians, 1 national outstanding youth and 25 senior professional scholars. The team members have covered neurosurgery, neurology, basic medicine, medical imaging, computer information technology, molecular imaging and other fields, forming an interdisciplinary team with neurosurgery precision medicine as the main body. Many PIs of the center have independent laboratories; the center is affiliated to the Peking University Third Hospital, with 8 MRI equipment and several CT equipment, which can carry out all routine head MRI and CT examinations; the key MRI laboratory, which has independently developed the world's first magnetic tracer extracellular space imaging equipment; neurosurgery, which has microscope, neuro-navigation equipment and electrophysiological monitoring equipment, etc.

Achievements in recent years:

1. The research team pioneered the magnetic tracer extracellular space imaging analysis method, which successfully solved the problem of deep tissue ECS signal acquisition, and realized the synchronous processing analysis and imaging display of the whole brain scale ECS structure and its internal molecular movement and other key information, and proposed the extracellular space drug delivery method based on this method.

2. The central research team has studied the gene ontology analysis of PLVAP in glioma, which has proved that the protein plays a major role in the immunobiological process related to glioma and in the inflammatory reaction. It was found that the degree of infiltration of most immune cells was positively correlated with the expression of PLVAP, which proved that PLVAP was significantly correlated with the degree of infiltration of immunosuppressive immune cells in glioma, the adverse survival rate and the adverse pathological type. Therefore, PLVAP was determined as a feasible marker and a promising target for accurate diagnosis and treatment strategies based on glioma.

3. The central research team systematically discussed its biological characteristics and clinical significance in adult gliomas. S100A10 was found to be a specific and sensitive indicator of mesenchymal molecular subtypes. The up-regulation of S100A10 level was independently associated with poor survival. Then we proved that S100A10 was positively correlated with most inflammatory genes except IgG, including HCK, LCK, MHC II, STAT1 and interferon. More importantly, the level of glial cells filtering immune cells is positively correlated with the expression of S100A10, making it a promising biomarker and potential target in the diagnosis, treatment and prognosis evaluation of glioma.

 

 

Director: YANG JUN

Contact: YU TAO

Email: 13901291211@163.com（Prof. YANG JUN ）